ACTU Stock Forecast & Price Target

Actuate Therapeutics is a promising biopharmaceutical company with a bright future due to the positive results from its recent Phase 2 study of elraglusib. These results showed a significant increase in median overall survival, a manageable safety profile, and a potential for long-term clinical benefit in first-line metastatic pancreatic cancer. Upcoming regulatory discussions and potential approval from the FDA and EMA could lead to accelerated market entry and partnerships, providing additional upside potential.

Actuate Therapeutics is evaluating conditional marketing authorization in the EU for its lead drug candidate elraglusib, despite the lack of approved GSK-3β inhibitors for the treatment of mPDAC patients with a 5-year survival rate of <5%. Despite the potential for non-dilutive funding opportunities through rare pediatric disease designations and priority review vouchers, the company has reported no revenues and a net loss of $0.20 per diluted share in 4Q25 and is projected to have a net loss of $0.72 per diluted share in 2026, leading to a reduced 12-month price target of $15 from $20.